Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2009-09-11
2011-12-20
Chandra, Gyan (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100
Reexamination Certificate
active
08080243
ABSTRACT:
The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
REFERENCES:
patent: 7261893 (2007-08-01), Veldman et al.
patent: 7456264 (2008-11-01), Keler et al.
patent: 2009/0142352 (2009-06-01), Jackson et al.
patent: WO 01/57081 (2001-08-01), None
patent: WO 2008/057457 (2008-05-01), None
patent: WO 2008/057458 (2008-05-01), None
patent: WO 2008/057459 (2008-05-01), None
patent: WO 2008/133647 (2008-11-01), None
patent: WO 2009/055783 (2009-04-01), None
Alborn et al., Clin. Chem. 53: 1814-1819, 2007.
Chamov and Ashkanazi, Tibtech 14: 52-60, 1996.
Rudikoff et al., Proc. Natl. Acad. Sci. 79: 1979-1983, 1982.
Wells, 1990, Biochemistry 29:8509-8517.
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.
Bottomley, M., et al., “Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants,”The Journal of Biological Chemistry, 2009, 1313-1323, vol. 284, No. 2.
Chan, J., et al., “A Proprotein Convertase Subtilisin/Kexin Type 9 Neutralizing Antibody Reduces Serum Cholesterol in Mice and Nonhuman Primates,”Proceedings of the National Academy of Sciences of the United States of America, 2009, 9820-9825, vol. 106, No. 24.
Cunningham, D., et al., “Structural and Biophysical Studies of PCSK9 and its Mutants Linked to Familial Hypercholesterolemia,”Nature Structural&Molecular Biology, 2007, 413-419, vol. 14, No. 5.
Grefhorst, A., et al., “Plasma PCSK9 Preferentially Reduces Liver LDL Receptors in Mice,”Journal of Lipid Research, 2008, 1303-1311, vol. 49.
Kwon, H., et al, “Molecular Basis for LDL Receptor Recognition by PCSK9,”Proceedings of the National Academy of Sciences of the United States of America, 2008, 1820-1825, vol. 105, No. 6.
Pandit, S., et al., “Functional Analysis of Sites within PCSK9 Responsible for Hypercholesterolemia,”Journal of Lipid Research, 2008, 1333-1343, vol. 49.
Peterson, A., et al, “PCSK9 Function and Physiology,”Journal of Lipid Research, 2008, 1595-1599, vol. 49.
Zhang, D., et al., “Structural Requirements for PCSK9-Mediated Degradation of the Low-Density Lipoprotein Receptor,”Proceedings of the National Academy of Sciences of the United States of America, 2008, 13045-13050, vol. 105, No. 35.
Frank-Kamenetsky, et al., “Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates,” Proceedings of the National Academy of Sciences of the United States, Aug. 2008, pp. 11915-11920, vol. 105, No. 33.
Graham, “Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice,”Journal of Lipid Research, Apr. 2007, pp. 763-767, vol. 48, No. 4.
Horton et al., “Molecular biology of PCSK9: its role in LDL metabolism,”Trends in Biochemical Sciences, 2007, pp. 71-77, vol. 32.
International Preliminary Examination Report issued Jun. 30, 2010, for International Patent Application No. PCT/IB2009/053990.
International Preliminary Examination Report issued Dec. 15, 2010, for International Patent Application No. PCT/IB2009/053990.
International Search Report mailed Jun. 1, 2010, for International Patent Application No. PCT/IB2009/053990.
Lopez, D., Inhibition of PCSK9 as a novel strategy for the treatment ofhypercholesterolemia, Drug News & Perspectives, 2008, pp. 323-330, vol. 21.
Lopez, D., “PCSK9: An enigmatic protease,”Biochemica and Biophysica Acta, 2008, pp. 184-191, vol. 1781.
McNutt M.C., et al., “Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells,”Journal of Biological Chemistry, 2009, pp. 10561-10570, vol. 284.
Official Communication issued Nov. 15, 2010, in connection with International Patent Application No. PCT/IB2009/053990.
Written Opinion of the ISA issued May 25, 2010, for International Patent Application No. PCT/IB2009/053990.
Abdiche Yasmina Noubia
Chaparro Riggers Javier Fernando
Gomes Bruce Charles
Hawkins Julie Jia Li
Liang Hong
Chandra Gyan
Pfizer Inc.
Pfizer Inc.
Rinat Neuroscience Corp.
LandOfFree
Isolated antibody which specifically binds to PCSK9 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated antibody which specifically binds to PCSK9, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated antibody which specifically binds to PCSK9 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4313280